It has been shown that vemurafenib or apatinib could significantly inhibit tumor growth in NSCLC patients with BRAF V600E mutantion who did not respond to conventional chemotherapy regimens [29, 30]. Here, BRAF is linked to non-small cell lung carcinoma.